BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia

NEXT STORY
New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool
PREV STORY
Teleflex Announces FDA Clearance for Expanded Indication of the UroLift® System for Treatment of Larger Prostates, Up to 100cc
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Synairgen plc – Interim results for the six months ended 30 June 2020

author_avatar
NASDAQ Market News

Patient Recruitment and Retention Services Market by Therapeutic Areas, Patient Recruitment Steps, Trial Phases, and Key Geographies – Global Forecast 2021-2030

author_avatar
NASDAQ Market News

Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer

- Collaboration will evaluate Radius’ investigational drug, RAD1901, in combination with Novartis investigational CDK4/6 ...

author_avatar
NASDAQ Market News